Comparison of Treatment-Emergent Extrapyramidal Symptoms in Patients With Bipolar Mania or Schizophrenia During Olanzapine Clinical Trials
J Clin Psychiatry 2006;67(1):107-113
© Copyright 2017 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Background: Previous research on
pharmacotherapy with conventional antipsychotics has
suggested that patients with affective disorders
have higher rates of treatment-emergent
extrapyramidal symptoms (EPS) than patients with
schizophrenia. It is not known whether this
differential vulnerability holds true for treatment with
atypical antipsychotics such as olanzapine. The
present analysis retrospectively examined
olanzapine clinical trial data for incidence of
treatment-emergent EPS in patients with either schizophrenia
or bipolar disorder.
Method: Study participants were 4417
patients meeting DSM-III or DSM-IV criteria for either schizophrenia or bipolar mania
participating in olanzapine clinical trials through July
31, 2001. Data were pooled across haloperidol-controlled trials and separately across
placebo-controlled trials. Measures of EPS included rates
of treatment-emergent EPS adverse event by type (i.e., dystonic, parkinsonian, or
residual), Simpson-Angus Scale score mean change,
rates of treatment-emergent parkinsonism, and rates
of anticholinergic use.
Results: Consistent with prior research,
haloperidol-treated patients with bipolar disorder
appeared to be more vulnerable to the development of EPS than those with schizophrenia.
However, olanzapine-treated patients with bipolar
disorder were no more likely to develop EPS than
those with schizophrenia.
Conclusion: Results support previous
research regarding conventional antipsychotics and
suggest that olanzapine therapy does not increase
the risk of EPS for patients with bipolar disorder.